Shanghai Fosun Pharmaceutical : VOLUNTARY ANNOUNCEMENT-REGARDING REGISTRATION APPROVAL OBTAINED BY A SUBSIDIARY IN RELATION TO COVID-19 TEST KIT (H SHARES)

Hong Kong Exchanges and Clearing Limited and The Hong Kong Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

ɪऎూ݋ᔼᖹ€ණྠٰ΅Ϟࠢʮ̡

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

VOLUNTARY ANNOUNCEMENT

REGARDING REGISTRATION APPROVAL OBTAINED BY A SUBSIDIARY

IN RELATION TO COVID-19 TEST KIT

This announcement is made by Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the "Company") on a voluntary basis.

The board of directors (the "Board") of the Company is pleased to announce that Fosun Diagnostic Technology (Shanghai) Co., Ltd.* (ూ݋ൢᓙ߅Ҧ€ɪऎϞࠢʮ̡) ("Fosun Diagnostic"), a subsidiary of the Company, has received the Medical Device Registration Certificate of the People's Republic of China (In Vitro Diagnostic Reagents) issued by the National Medical Products Administration of the People's Republic of China ("PRC") (the "Approval") for the use of the Coronavirus (2019-nCoV) Antigen Test Kit (Colloidal Gold Chromatographic Immunoassay) (the "Product") developed by Fosun Diagnostic. Pursuant to the approval, the Product will be officially launched in Mainland China (excluding the Hong Kong Special Administrative Region, the Macau Administrative Region, and Taiwan Region).

Further information of the Product is set out as follows:

Name of the Product:	Coronavirus (2019-nCoV) Antigen Test Kit (Colloidal Gold
Chromatographic Immunoassay)
Registration Number:	Guo Xie Zhu Zhun 20223400504* (਷૛ءࡘ20223400504)
Name of Registrant:	Fosun Diagnostic
Registration Category:	Class III
Date of Registration Approval:	13 April 2022
Validity Period of Registration:	Until 12 April 2023
1

The Product is used to qualitatively detect, in vitro, novel coronavirus (2019-nCoV) nucleocapsid (N) antigen in nasal swab samples. It is suitable for patients with acute infection. The nasal swab samples used for the test can be collected and tested by medical staff or the person being tested. The Product is not to be used alone in the diagnosis of novel coronavirus infections. A positive result only indicates that there may be specific antigens in the sample, and the infection status should be determined based on the nucleic acid test results. A negative result does not rule out novel coronavirus infection, and should not be used as the sole basis for making treatment and disease management decisions. Suspected patients experiencing the relevant clinical symptoms should carry out further nucleic acid test regardless of the test results indicated by the Product.

The applicable range of people and the use of the Product will be subject to applicable laws and regulations, including the Pilot Scheme for Coronavirus Antigen Test Applications* (อڿषݭҤࡡᏨ಻ Ꮠ͜˙ࣩ€༊Б) of the PRC.

The Product has received a number of registration and certification overseas, including the European Union's (EU) Conformitè Europëenne (CE) certification, the German BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte) registration, and it is included in the EU Health Safety Committee's Common List (which is a recognized whitelist in the EU).

The sales performance of the Product in Mainland China will be subject to a number of factors including but not limited to demands arising from pandemic control measures, supply of raw materials, production and supply chain capabilities, market competition landscape and distribution channels, in which there exist uncertainties. Shareholders and potential investors should exercise caution when dealing in the securities of the Company.

By order of the Board

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Wu Yifang

Chairman

Shanghai, the PRC

13 April 2022

As at the date of this announcement, the executive directors of the Company are Mr. Wu Yifang, Mr. Wang Kexin and Ms. Guan Xiaohui; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang, Mr. Xu Xiaoliang and Mr. Pan Donghui; and the independent non-executive directors of the Company are Ms. Li Ling, Mr. Tang Guliang, Mr. Wang Quandi and Mr. Yu Tze Shan Hailson.

* For identification purpose only

2